FDA warns India’s Reliance Life Sciences about significant CGMP violations in its production of finished drugs.
FDA warns Jabil Inc. about significant CGMP violations at its Pharmaceutics International unit in Cockeysville, MD.
FDA warns India’s Reliance Life Sciences about significant CGMP violations in its production of finished drugs.
FDA warns Jabil Inc. about significant CGMP violations at its Pharmaceutics International unit in Cockeysville, MD.
Novartis and Bristol Myers Squibb confirm to BioSpace that they are suspending some CAR T candidate trials to evaluate adverse events that included deaths.
FDA adds a new frequently asked questions section to its Web page on PFAS (per- and polyfluoroalkyl substances) in medical devices, saying it has found no evidence that certain PFAS materials are harming patients.
